Adjuvant chemotherapy for resected non-small-cell lung cancer-ANITA takes the stage

Lancet Oncology

Volumn 7, Issue 9, 2006, Pages 701-703

  Azzoli, Christopher G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; NAVELBINE; PACLITAXEL; RAS PROTEIN; RNA;

AGE DISTRIBUTION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG INDICATION; DRUG MEGADOSE; FATIGUE; GENE EXPRESSION PROFILING; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; MICROARRAY ANALYSIS; NAUSEA; PHARMACOGENETICS; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; SURVIVAL RATE;

EID: 33747847150     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(06)70838-5     Document Type: Letter

References (13)

1. Douillard J.-Y., Rosell R., De Lena M., et al. Adjuvant vinorelbine plus cisplatin versus observation in completely resected stage IB-IIIA non-small-cell lung cancer patients (Adjuvant Navelbine International Trialist Association [ANITA]). Lancet Oncol 7 (2006) 719-727
2. Winton T., Livingston R., Johnson D., et al. Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer. N Engl J Med 352 (2005) 2589-2597
3. Arriagada R., Bergman B., Dunant A., et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 (2004) 351-360
4. Pignon J., Tribodet H., Scagliotti G., et al. Lung adjuvant cisplatin evaluation (LACE): a pooled analysis of five randomized clinical trials including 4584 patients. J Clin Oncol 24 suppl (2006) 366s
5. Pepe C., Hasan B., Winton T., et al. Adjuvant chemotherapy in elderly patients: an analysis of National Institute of Canada Clinical Trials Group and Intergroup BR.10. J Clin Oncol 24 suppl (2006) 366s
6. Kato H., Ichinose Y., Ohta M., et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350 (2004) 1713-1721
7. Strauss G., Herndon J., Maddaus M., et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol 24 suppl (2006) 365s
8. Soria J., Haddad V., Olaussen K., et al. Immunohistochemical staining of the excision repair cross-complementing 1 (ERCC1) protein as predictor for benefit of adjuvant chemotherapy (CT) in the International Lung Cancer Trial (IALT). J Clin Oncol 24 suppl (2006) 366s
9. Paz-Ares L., Sanchez J., Garcia-Velasco A., et al. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). J Clin Oncol 24 suppl (2006) 369s
10. Cappuzzo F., Toschi L., Trisolini R., et al. Clinical and biological effects of gefitinib in EGFR FISH positive/phospho-akt positive or never smoker non-small cell lung cancer (NSCLC): preliminary results of the ONCOBELL trial. J Clin Oncol 24 suppl (2006) 369s
11. Inoue A., Suzuki T., Fukuhara T., et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 24 (2006) 3340-3346
12. Kris M., Pao W., Zakowski M., et al. Prospective trial with preoperative gefitinib to correlate lung cancer repsonse with EGFR exon 19 and 21 mutations and to select patients for adjuvant therapy. J Clin Oncol 24 suppl (2006) 369s
13. Potti A., Mukherjee S., Petersen R., et al. A genomic strategy to refine prognosis in early-stage non-small cell lung cancer. N Engl J Med 355 (2006) 570-580